about
Core signaling pathways in human pancreatic cancers revealed by global genomic analysesAberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinomaSerial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer.Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinomaIn vivo and in vitro propagation of intraductal papillary mucinous neoplasms.Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreasThe Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinomaInhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signalingPdx1 expression in pancreatic precursor lesions and neoplasms.Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma.Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancerPrevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populWidespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia.A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.
P50
Q24606006-0F591FB8-1039-4F16-BA57-3ECE1B79B2CAQ24627680-ED791007-74E3-4D27-86D5-2588E9204A02Q33331290-E568FD4F-1EA6-4770-88E1-035A68F9AADFQ33698761-C81DD49A-4CED-460B-885D-BB5D0D13E824Q33911620-F81033CE-AB73-496A-9614-0BBC0B40C3DFQ34100230-D2A15E0F-C1BA-4B34-B78C-F6A2F32394C2Q34515144-93656485-C26C-4F18-9CFE-A8A5AEDD87DDQ34764696-BF32A3E2-9962-42AD-A9F4-A680FEDBB431Q35068809-6E3A638F-F34A-4A1E-87DC-F4794174AC8EQ35123631-27701C30-CEB2-4BBC-B68E-DDE589C04046Q35194671-BE74C0D4-2BF3-4B59-908D-843CC9C6BBEFQ35235698-4FA289F1-44CE-4E45-8E6B-AB60759973D5Q36647007-AC942346-C8CA-42C5-9BC3-E7344618AC40Q38351606-F695E077-F52D-4774-BB35-AC8FFD4E18B3Q39452730-73E0B6B9-E19E-4C5E-B995-7B483115F033Q39469747-28779C3F-31B1-45BE-85DE-0784C9007679Q41816001-89CD78CF-0A42-4099-AF61-F543AF982BE9
P50
name
Anirban Maitra
@ast
Anirban Maitra
@en
Anirban Maitra
@es
Anirban Maitra
@nl
type
label
Anirban Maitra
@ast
Anirban Maitra
@en
Anirban Maitra
@es
Anirban Maitra
@nl
prefLabel
Anirban Maitra
@ast
Anirban Maitra
@en
Anirban Maitra
@es
Anirban Maitra
@nl